-
Product Insights
NewALK Tyrosine Kinase Receptor – Drugs In Development, 2024
The ALK Tyrosine Kinase Receptor pipeline drugs market research report outlays comprehensive information on the ALK Tyrosine Kinase Receptor targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers products from therapy areas such as Oncology, Genetic Disorders, Non Malignant Disorders, and Undisclosed which include indications of Non-Small Cell Lung Cancer, Solid Tumor, Neurofibromatoses Type II, Letterer-Siwe Disease (Multifocal and multisystemic (disseminated) Langerhans-cell histiocytosis), Inflammatory...
-
Innovation Ranking
Innovation Ranking – ALK-Abello AS
ALK-Abello AS (ALK), a subsidiary of The Lundbeck Foundation, discovers, develops, and commercializes immunotherapies to treat and prevent allergies. The company's allergy immunotherapy product portfolio includes tablets, sublingual or drop-based vaccines, subcutaneous vaccines, and adrenaline auto-injectors to treat severe allergic reactions in emergencies (anaphylaxis). ALK’s research and development pipeline products include sublingual immunotherapy tablets for addressing ragweed, house dust mite, and tree pollen allergy. The company’s products target allergies caused by grass, tree, ragweed, house dust mite, Japanese cedar, and...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ALKS-2680 in Idiopathic Hypersomnia (IH)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ALKS-2680 in Idiopathic Hypersomnia (IH) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ALKS-2680 in Idiopathic Hypersomnia (IH) Drug Details: ALKS-2680 is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ALKS-2680 in Type 1 Narcolepsy (Narcolepsy with Cataplexy)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ALKS-2680 in Type 1 Narcolepsy (Narcolepsy with Cataplexy) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ALKS-2680 in Type 1 Narcolepsy (Narcolepsy with...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ALKS-2680 in Type 2 Narcolepsy (Narcolepsy without Cataplexy)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ALKS-2680 in Type 2 Narcolepsy (Narcolepsy without Cataplexy) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ALKS-2680 in Type 2 Narcolepsy (Narcolepsy without...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Lorlatinib in Neuroblastoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Lorlatinib in Neuroblastoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Lorlatinib in Neuroblastoma Drug Details: Lorlatinib (Lorviqua / Lorbrena/ Lorlak) is a...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Alectinib in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Alectinib in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Alectinib in Solid Tumor Drug Details: Alectinib (Alecensa / Alecensaro) is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Brigatinib in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Brigatinib in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Brigatinib in Solid Tumor Drug Details: Brigatinib (AP-26113, Alunbrig, Evobrig) is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Brigatinib in Vestibular Schwannoma (Acoustic Neuroma)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Brigatinib in Vestibular Schwannoma (Acoustic Neuroma) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Brigatinib in Vestibular Schwannoma (Acoustic Neuroma) Drug Details: Brigatinib...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Crizotinib in Uveal Melanoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Crizotinib in Uveal Melanoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Crizotinib in Uveal Melanoma Drug Details: Crizotinib (Xalkori, Crizalk) is a...